HK2 and urinary bladder carcinoma: Experimental inhibition of HK2 via 2-deoxy-D-glucose (2-DG) has demonstrated promising antitumor effects in vitro and in vivo, indicating the potential therapeutic value of targeting glucose metabolism in bladder cancer 58, 59.